| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T99089 | ||||
| Target Name | Serine/threonine-protein kinase B-raf (BRAF) | ||||
| Type of Target |
Successful |
||||
| Drug Potency against Target | Sorafenib | Drug Info | Ki = 22 nM | [1] | |
| Vemurafenib | Drug Info | IC50 = 100 nM | [2] | ||
| References | |||||
| REF 1 | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. | ||||
| REF 2 | Inhibitors of c-jun-N-terminal kinase (JNK). Mini Rev Med Chem. 2008 Jul;8(8):755-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.